{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:00:27Z","timestamp":1794589227328,"version":"4.9.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.schres.2016.02.001","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T09:50:04Z","timestamp":1456480204000},"page":"152-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study"],"prefix":"10.1016","volume":"172","author":[{"given":"Robert E.","family":"Litman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Raines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lev","family":"Gertsik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Zukin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2016.02.001_bb0005","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2016.02.001_bb0010","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.euroneuro.2014.03.007","article-title":"A phase II\/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia \u2014 results from the CandleLyte study","volume":"24","author":"Bugarski-Kirola","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.schres.2016.02.001_bb0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2009.12.041","article-title":"Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia","volume":"639","author":"Chaki","year":"2010","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.schres.2016.02.001_bb0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tips.2008.10.006","article-title":"Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"issue":"4\u20136","key":"10.1016\/j.schres.2016.02.001_bb0025","first-page":"365","article-title":"Glutamate and schizophrenia: beyond the dopamine hypothesis","volume":"26","author":"Coyle","year":"2006","journal-title":"Cell. Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.schres.2016.02.001_bb0030","doi-asserted-by":"crossref","first-page":"359","DOI":"10.31887\/DCNS.2010.12.3\/jcoyle","article-title":"Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia","volume":"12","author":"Coyle","year":"2010","journal-title":"Dialogues Clin. Neurosci."},{"issue":"S26","key":"10.1016\/j.schres.2016.02.001_bb0035","article-title":"AZD8529 \u2014 an mGluR2 positive allosteric modulator for the treatment of schizophrenia","volume":"38","author":"Cross","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.schres.2016.02.001_bb0040","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1017\/S1461145712000314","article-title":"Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study","volume":"16","author":"de la Fuente-Sandoval","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.schres.2016.02.001_bb0045","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamapsychiatry.2013.289","article-title":"Glutamate levels in the associative striatum before and after 4weeks of antipsychotic treatment in first-episode psychosis","volume":"70","author":"de la Fuente-Sandoval","year":"2013","journal-title":"JAMA Psychiatry."},{"issue":"5","key":"10.1016\/j.schres.2016.02.001_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.biopsych.2013.06.011","article-title":"Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function","volume":"75","author":"Demjaha","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2016.02.001_bb0055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/schbul\/sbt236","article-title":"Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia","volume":"40","author":"Gill","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2016.02.001_bb0060","series-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","first-page":"534","article-title":"Abnormal Involuntary Movements Scale (AIMS)","author":"Guy","year":"1976"},{"key":"10.1016\/j.schres.2016.02.001_bb0065","series-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","first-page":"217","article-title":"Clinical global impression","author":"Guy","year":"1976"},{"issue":"10","key":"10.1016\/j.schres.2016.02.001_bb0070","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2016.02.001_bb0075","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.schres.2016.02.001_bb0080","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia","volume":"31","author":"Kinon","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2016.02.001_bb0085","series-title":"Handbook of Psychiatric Measures","article-title":"Structured clinical interview for DSM-IV Axis I disorders (SCID I)","author":"Koback","year":"2008"},{"key":"10.1016\/j.schres.2016.02.001_bb0090","series-title":"Presented at: American College of Neuropsychopharmacology Annual Meeting; Hollywood, Florida","article-title":"Efficacy of an mGluR2 agonist (LY354740) and an mGluR2 positive allosteric modulator (AZD8529) in attenuating ketamine effects in humans","author":"Krystal","year":"2013"},{"issue":"1","key":"10.1016\/j.schres.2016.02.001_bb0095","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00213-004-1982-8","article-title":"Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects","volume":"179","author":"Krystal","year":"2005","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.schres.2016.02.001_bb0100","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nn.3181","article-title":"HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity","volume":"15","author":"Kurita","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.schres.2016.02.001_bb0105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pnpbp.2015.02.012","article-title":"Perspectives on the mGluR2\/3 agonists as a therapeutic target for schizophrenia: still promising or a dead end?","volume":"6","author":"Li","year":"2015","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2016.02.001_bb0110","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.pbb.2011.03.023","article-title":"Glutamate signaling in the pathophysiology and therapy of schizophrenia","volume":"100","author":"Lin","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"23","key":"10.1016\/j.schres.2016.02.001_bb0115","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1007\/s00018-009-0130-3","article-title":"Group II metabotropic glutamate receptors and schizophrenia","volume":"66","author":"Moreno","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"issue":"9","key":"10.1016\/j.schres.2016.02.001_bb0120","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.schres.2016.02.001_bb0125","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/13803390802592458","article-title":"A comparison of the cogstate schizophrenia battery and the measurement and treatment research to improve cognition in schizophrenia (MATRICS) battery in assessing cognitive impairment in chronic schizophrenia","volume":"31","author":"Pietrzak","year":"2009","journal-title":"J. Clin. Exp. Neuropsychol."},{"issue":"4","key":"10.1016\/j.schres.2016.02.001_bb0130","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0269881115573403","article-title":"Pharmacokinetic and pharmacodynamics characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomized, double-blind phase-1 studies","volume":"29","author":"Salih","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"212","key":"10.1016\/j.schres.2016.02.001_bb0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"45","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"2\u20133","key":"10.1016\/j.schres.2016.02.001_bb0140","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.schres.2013.08.020","article-title":"Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo","volume":"150","author":"Stauffer","year":"2013","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2016.02.001_bb0145","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2016.02.001_bb0150","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.neuropharm.2011.05.005","article-title":"Metabotropic glutamate receptors as therapeutic targets for schizophrenia","volume":"62","author":"Vinson","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2016.02.001_bb0155","first-page":"S141","article-title":"Striatal activation induced by mGluR2 positive allosteric modulation correlates with negative symptom reduction in schizophrenia","volume":"38","author":"Wolf","year":"2013","journal-title":"Neuropsychopharmacology"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416300573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416300573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T09:31:53Z","timestamp":1654421513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996416300573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":31,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0920996416300573"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2016.02.001","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2016.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}